Martine Piccart, MD, PhD: No Benefit in Extending Herceptin in HER2 Breast Cancer

Dr. Martine Piccart sits down with Selma Schimmel and The Group Room at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).  They discuss the results of a study she authored for patients with human epidermal growth factor receptor 2 (HER2)–positive early–stage breast cancer — one year of adjuvant trastuzumab (Herceptin) should remain the standard of care, according to a study presented.

Martine Piccart, MD, PhD is the current President of the European Society For Medical Oncology (ESMO) and Professor of Oncology at the Université Libre de Bruxelles (ULB) and Director of the Medicine Department at the Institut Jules Bordet, in Brussels, Belgium.

Advocacy and educational support provided in part by:

Eisai Lilly Logos SABCS 2012

Comments